Lumasiran · OXLUMO
RNA / oligonucleotide
Evidence outlook
Approved: Primary Hyperoxaluria Type 1
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients (OXLUMO)
- Primary hyperoxaluria type 1 (PH1) in all age groups
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ILLUMINATE-C NCT04152200 · Primary Hyperoxaluria Type 1 This was a single-arm, open-label study with no control group, so any change cannot be separated from natural disease fluctuation or other factors. It was designed to characterize lumasiran in a more advanced, higher-risk population than the earlier placebo-controlled trial. Registry: NCT04152200 | 3 | Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6; Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6 2021-05-18 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 1 more trial
ILLUMINATE-A NCT03681184 · Primary Hyperoxaluria Type 1 This was a randomized, quadruple-blind, placebo-controlled trial in 39 patients. The primary endpoint, urinary oxalate excretion (the biochemical measure that defines this disease), fell by 65% with lumasiran versus 12% with placebo, a highly statistically significant difference (p<0.0001). Registry: NCT03681184 | 3 | Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 2019-11-05 | Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 (Baseline to Month 6): Placebo/Lumasiran -11.8 percent change (Standard Error 3.8) | Lumasiran/Lumasiran -65.4 percent change (Standard Error 2.9) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Primary Hyperoxaluria Type 1: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lumasiran (OXLUMO): this drug | Approved | RNA / oligonucleotide | HAO1 (glycolate oxidase) | Weak signal | NCT03681184: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 (Baseline to Month 6): Placebo/Lumasiran -11.8 percent change (Standard Error 3.8) | Lumasiran/Lumasiran -65.4 percent change (Standard Error 2.9) | |
| Nedosiran (Rivfloza) | Approved | RNA / oligonucleotide | LDHA (lactate dehydrogenase A) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Phase 3 | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.